Gilead Sciences (GILD) 94.91 $GILD
3 Biotech Stocks With a Higher Profit Margin Than Gilead Sciences, Inc.
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 03, 10:16AM CST
Source: StockMonkeys.com via Flickr. It's been a truly transformative year for Gilead Sciences and its shareholders. Even taking into consideration the latest swoon in Gilead's share price tied to the approval of AbbVie 's Viekira Pak and...
GILD: 94.91 (+0.65), ADMS: 17.49 (+0.12), ABBV: 65.89 (+0.45), ENTA: 50.45 (-0.40), PDLI: 7.68 (-0.03)
How These 3 Stocks Doubled Investors' Money in Q4
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 03, 9:31AM CST
Source: Flickr user Tax Credits Most of the time, life-changing financial gains are generated over the long haul, not in the blink of an eye. However, sometimes stocks can put up jaw-dropping returns over a short period of time too. For example,...
BLUE: 91.26 (-0.46), ISIS: 61.57 (-0.17), ALNY: 97.77 (+0.77), OVAS: 45.83 (+1.61), GILD: 94.91 (+0.65), RGLS: 17.19 (+1.15), CELG: 113.52 (+1.66)
The 3 Underlying Reasons Why Gilead Sciences, Inc. Could Remain Wildly Successful
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 03, 6:52AM CST
Source: Flickr user Sergei Golyshev. If you think you've done well since the stock market hit its lows more than five years ago, Gilead Sciences shareholders would love to have a word, even despite the stock's recent slip. Shares of...
GILD: 94.91 (+0.65)
Final Glance: Biotechnology companies
AP - Fri Jan 02, 5:52PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
Seeking Alpha's Biotech Weekly: 2014's Approval-Palooza, Ebola In Scotland, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 02, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACC: 42.09 (+0.73), JNJ: 104.52 (-0.05), NVO: 42.49 (+0.17), OGXI: 2.32 (+0.03), GILD: 94.91 (+0.65), ONVO: 7.29 (+0.04), TKMR: 14.76 (-0.39), TEVA: 56.22 (-1.29), MDXG: 9.74 (-1.79)
Midday Glance: Biotechnology companies
AP - Fri Jan 02, 12:20PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
Individual Investor Portfolio: Solid Results, But Energy Sell-Off And Biotechnology Add Volatility
James Sands - at Seeking Alpha - Fri Jan 02, 9:45AM CST
KMI: 42.81 (+0.50), BIIB: 342.01 (+2.56), ANET: 62.68 (+1.92), PCYC: 124.46 (+2.20), MKC: 73.95 (-0.35), HSY: 103.71 (-0.22), JBHT: 83.21 (-1.04), SFM: 34.02 (+0.04), GWW: 255.22 (+0.33), GOOG: 524.81 (-1.59), PCP: 238.44 (-2.44), SNI: 75.94 (+0.67), UPS: 110.38 (-0.79), PEP: 94.44 (-0.12), T: 33.87 (+0.28), CMI: 146.42 (+2.25), AAPL: 109.33 (-1.05), UNP: 118.61 (-0.52), PSX: 72.29 (+0.59), NSC: 109.15 (-0.46), FB: 78.45 (+0.43), VFC: 73.76 (-1.14), DISCA: 34.48 (+0.03), COP: 68.92 (-0.14), WFC: 54.70 (-0.12), TSN: 39.95 (-0.14), CELG: 113.52 (+1.66), WWAV: 34.76 (-0.23), PXD: 149.89 (+1.04), GILD: 94.91 (+0.65), PG: 90.44 (-0.65)
Early Glance: Biotechnology companies
AP - Fri Jan 02, 9:21AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
How 1 Tiny Hepatitis C Drug Developer Trounced Gilead Sciences, Inc. in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Jan 02, 6:51AM CST
Source: Regulus Therapeutics via Google Maps. Gilead Sciences got all the press last year thanks to its hepatitis C drugs Sovaldi and Harvoni, but despite its 27% return in 2014, Gilead Sciences wasn't the best-performing hepatitis C drug stock...
JNJ: 104.52 (-0.05), ISIS: 61.57 (-0.17), ALNY: 97.77 (+0.77), GILD: 94.91 (+0.65), RGLS: 17.19 (+1.15)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 42.49 (+0.17), RPTP: 10.40 (-0.12), ISIS: 61.57 (-0.17), GILD: 94.91 (+0.65), GALT: 3.40 (-0.07), ICPT: 159.49 (+3.49), TBRA: ()
Bull of the Day: Incyte (INCY) - Bull of the Day
Kevin Cook - ZACKS - Fri Jan 02, 12:00AM CST
Bull of the Day: Incyte (INCY) - Bull of the Day
PCYC: 124.46 (+2.20), GILD: 94.91 (+0.65), SGEN: 32.54 (+0.41), INCY: 73.76 (+0.65), ABBV: 65.89 (+0.45), AGIO: 109.76 (-2.28)
5 Biotech Stocks With Big News Due In January
at Investor's Business Daily - Wed Dec 31, 12:15PM CST
The biotech industry is set to hit the ground running in 2015, with January alone bringing a passel of potentially stock-moving events by some of the biggest players. The second full week of the month will bring the annual JPMorgan Healthcare...
BIIB: 342.01 (+2.56), ESRX: 84.65 (-0.02), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), CELG: 113.52 (+1.66)
These 3 Biotechs Are Looking at a Happy New Year
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 31, 11:33AM CST
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year. If your portfolio could use some exposure to healthcare and biotechs, join the Fool's...
NFLX: 348.94 (+7.33), MDVN: 101.79 (+2.18), JNJ: 104.52 (-0.05), AMZN: 308.52 (-1.83), JPM: 62.49 (-0.09), GILD: 94.91 (+0.65), AGIO: 109.76 (-2.28), AAPL: 109.33 (-1.05), XLRN: 38.26 (-0.70), CELG: 113.52 (+1.66)
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Vertex Pharmaceuticals and Achillion Pharmaceuticals
PR Newswire - Wed Dec 31, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Gilead Sciences Inc. (Nasdaq:GILD-Free Report), AbbVie (NYSE:ABBV-Free Report), Vertex Pharmaceuticals Inc. (Nasdaq:VRTX-Free Report) and Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report).
VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65)
RBC provides commentary on Viekira Pak ramp up
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 7:12AM CST
GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45)
Most active Nasdaq-traded stocks
AP - Tue Dec 30, 5:31PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 34.75 (-0.26), GILD: 94.91 (+0.65), FB: 78.45 (+0.43), ARCP: 9.27 (+0.22), MSFT: 46.76 (+0.31), INTC: 36.36 (+0.07), AAPL: 109.33 (-1.05), CSCO: 27.61 (-0.21)
3 Biotech Stocks With a Higher Profit Margin Than Gilead Sciences, Inc.
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 03, 10:16AM CST
Source: StockMonkeys.com via Flickr. It's been a truly transformative year for Gilead Sciences and its shareholders. Even taking into consideration the latest swoon in Gilead's share price tied to the approval of AbbVie 's Viekira Pak and...
GILD: 94.91 (+0.65), ADMS: 17.49 (+0.12), ABBV: 65.89 (+0.45), ENTA: 50.45 (-0.40), PDLI: 7.68 (-0.03)
How These 3 Stocks Doubled Investors' Money in Q4
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 03, 9:31AM CST
Source: Flickr user Tax Credits Most of the time, life-changing financial gains are generated over the long haul, not in the blink of an eye. However, sometimes stocks can put up jaw-dropping returns over a short period of time too. For example,...
BLUE: 91.26 (-0.46), ISIS: 61.57 (-0.17), ALNY: 97.77 (+0.77), OVAS: 45.83 (+1.61), GILD: 94.91 (+0.65), RGLS: 17.19 (+1.15), CELG: 113.52 (+1.66)
The 3 Underlying Reasons Why Gilead Sciences, Inc. Could Remain Wildly Successful
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 03, 6:52AM CST
Source: Flickr user Sergei Golyshev. If you think you've done well since the stock market hit its lows more than five years ago, Gilead Sciences shareholders would love to have a word, even despite the stock's recent slip. Shares of...
GILD: 94.91 (+0.65)
Final Glance: Biotechnology companies
AP - Fri Jan 02, 5:52PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
Seeking Alpha's Biotech Weekly: 2014's Approval-Palooza, Ebola In Scotland, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 02, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACC: 42.09 (+0.73), JNJ: 104.52 (-0.05), NVO: 42.49 (+0.17), OGXI: 2.32 (+0.03), GILD: 94.91 (+0.65), ONVO: 7.29 (+0.04), TKMR: 14.76 (-0.39), TEVA: 56.22 (-1.29), MDXG: 9.74 (-1.79)
Midday Glance: Biotechnology companies
AP - Fri Jan 02, 12:20PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
Individual Investor Portfolio: Solid Results, But Energy Sell-Off And Biotechnology Add Volatility
James Sands - at Seeking Alpha - Fri Jan 02, 9:45AM CST
KMI: 42.81 (+0.50), BIIB: 342.01 (+2.56), ANET: 62.68 (+1.92), PCYC: 124.46 (+2.20), MKC: 73.95 (-0.35), HSY: 103.71 (-0.22), JBHT: 83.21 (-1.04), SFM: 34.02 (+0.04), GWW: 255.22 (+0.33), GOOG: 524.81 (-1.59), PCP: 238.44 (-2.44), SNI: 75.94 (+0.67), UPS: 110.38 (-0.79), PEP: 94.44 (-0.12), T: 33.87 (+0.28), CMI: 146.42 (+2.25), AAPL: 109.33 (-1.05), UNP: 118.61 (-0.52), PSX: 72.29 (+0.59), NSC: 109.15 (-0.46), FB: 78.45 (+0.43), VFC: 73.76 (-1.14), DISCA: 34.48 (+0.03), COP: 68.92 (-0.14), WFC: 54.70 (-0.12), TSN: 39.95 (-0.14), CELG: 113.52 (+1.66), WWAV: 34.76 (-0.23), PXD: 149.89 (+1.04), GILD: 94.91 (+0.65), PG: 90.44 (-0.65)
Early Glance: Biotechnology companies
AP - Fri Jan 02, 9:21AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 94.91 (+0.65), AMGN: 159.89 (+0.60), CELG: 113.52 (+1.66)
How 1 Tiny Hepatitis C Drug Developer Trounced Gilead Sciences, Inc. in 2014
Todd Campbell, The Motley Fool - Motley Fool - Fri Jan 02, 6:51AM CST
Source: Regulus Therapeutics via Google Maps. Gilead Sciences got all the press last year thanks to its hepatitis C drugs Sovaldi and Harvoni, but despite its 27% return in 2014, Gilead Sciences wasn't the best-performing hepatitis C drug stock...
JNJ: 104.52 (-0.05), ISIS: 61.57 (-0.17), ALNY: 97.77 (+0.77), GILD: 94.91 (+0.65), RGLS: 17.19 (+1.15)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 42.49 (+0.17), RPTP: 10.40 (-0.12), ISIS: 61.57 (-0.17), GILD: 94.91 (+0.65), GALT: 3.40 (-0.07), ICPT: 159.49 (+3.49), TBRA: ()
Bull of the Day: Incyte (INCY) - Bull of the Day
Kevin Cook - ZACKS - Fri Jan 02, 12:00AM CST
Bull of the Day: Incyte (INCY) - Bull of the Day
PCYC: 124.46 (+2.20), GILD: 94.91 (+0.65), SGEN: 32.54 (+0.41), INCY: 73.76 (+0.65), ABBV: 65.89 (+0.45), AGIO: 109.76 (-2.28)
5 Biotech Stocks With Big News Due In January
at Investor's Business Daily - Wed Dec 31, 12:15PM CST
The biotech industry is set to hit the ground running in 2015, with January alone bringing a passel of potentially stock-moving events by some of the biggest players. The second full week of the month will bring the annual JPMorgan Healthcare...
BIIB: 342.01 (+2.56), ESRX: 84.65 (-0.02), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), CELG: 113.52 (+1.66)
These 3 Biotechs Are Looking at a Happy New Year
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 31, 11:33AM CST
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year. If your portfolio could use some exposure to healthcare and biotechs, join the Fool's...
NFLX: 348.94 (+7.33), MDVN: 101.79 (+2.18), JNJ: 104.52 (-0.05), AMZN: 308.52 (-1.83), JPM: 62.49 (-0.09), GILD: 94.91 (+0.65), AGIO: 109.76 (-2.28), AAPL: 109.33 (-1.05), XLRN: 38.26 (-0.70), CELG: 113.52 (+1.66)
The Zacks Analyst Blog Highlights: Gilead Sciences, AbbVie, Vertex Pharmaceuticals and Achillion Pharmaceuticals
PR Newswire - Wed Dec 31, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Gilead Sciences Inc. (Nasdaq:GILD-Free Report), AbbVie (NYSE:ABBV-Free Report), Vertex Pharmaceuticals Inc. (Nasdaq:VRTX-Free Report) and Achillion Pharmaceuticals (Nasdaq:ACHN-Free Report).
VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65)
RBC provides commentary on Viekira Pak ramp up
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 7:12AM CST
GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45)
Most active Nasdaq-traded stocks
AP - Tue Dec 30, 5:31PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 34.75 (-0.26), GILD: 94.91 (+0.65), FB: 78.45 (+0.43), ARCP: 9.27 (+0.22), MSFT: 46.76 (+0.31), INTC: 36.36 (+0.07), AAPL: 109.33 (-1.05), CSCO: 27.61 (-0.21)
